GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on Aug. 7. The company beat estimates for both earnings and sales. Sales of ...

Joshua Fredell, Pharm.D., senior vice president at CVS Caremark, says innovation in PBMs comes from simplifying pricing, offering flexible benefit designs, and using technology to create a smoother ...

Mounjaro / Zepbound (tirzepatide): Targets both GLP-1 and GIP receptors to help curb cravings and keep you full longer. Mochi cites studies showing weight loss of up to 22.5% with ongoing use.